390 related articles for article (PubMed ID: 29747685)
21. Engineered CAR T Cells Targeting the Cancer-Associated Tn-Glycoform of the Membrane Mucin MUC1 Control Adenocarcinoma.
Posey AD; Schwab RD; Boesteanu AC; Steentoft C; Mandel U; Engels B; Stone JD; Madsen TD; Schreiber K; Haines KM; Cogdill AP; Chen TJ; Song D; Scholler J; Kranz DM; Feldman MD; Young R; Keith B; Schreiber H; Clausen H; Johnson LA; June CH
Immunity; 2016 Jun; 44(6):1444-54. PubMed ID: 27332733
[TBL] [Abstract][Full Text] [Related]
22. CD28 cosignalling does not affect the activation threshold in a chimeric antigen receptor-redirected T-cell attack.
Chmielewski M; Hombach AA; Abken H
Gene Ther; 2011 Jan; 18(1):62-72. PubMed ID: 20944680
[TBL] [Abstract][Full Text] [Related]
23.
Stüber T; Monjezi R; Wallstabe L; Kühnemundt J; Nietzer SL; Dandekar G; Wöckel A; Einsele H; Wischhusen J; Hudecek M
J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32303620
[TBL] [Abstract][Full Text] [Related]
24. T cells expressing a chimeric antigen receptor that binds hepatitis B virus envelope proteins control virus replication in mice.
Krebs K; Böttinger N; Huang LR; Chmielewski M; Arzberger S; Gasteiger G; Jäger C; Schmitt E; Bohne F; Aichler M; Uckert W; Abken H; Heikenwalder M; Knolle P; Protzer U
Gastroenterology; 2013 Aug; 145(2):456-65. PubMed ID: 23639914
[TBL] [Abstract][Full Text] [Related]
25. Control of triple-negative breast cancer using ex vivo self-enriched, costimulated NKG2D CAR T cells.
Han Y; Xie W; Song DG; Powell DJ
J Hematol Oncol; 2018 Jul; 11(1):92. PubMed ID: 29980239
[TBL] [Abstract][Full Text] [Related]
26. Incorporation of a hinge domain improves the expansion of chimeric antigen receptor T cells.
Qin L; Lai Y; Zhao R; Wei X; Weng J; Lai P; Li B; Lin S; Wang S; Wu Q; Liang Q; Li Y; Zhang X; Wu Y; Liu P; Yao Y; Pei D; Du X; Li P
J Hematol Oncol; 2017 Mar; 10(1):68. PubMed ID: 28288656
[TBL] [Abstract][Full Text] [Related]
27. A TIGIT-based chimeric co-stimulatory switch receptor improves T-cell anti-tumor function.
Hoogi S; Eisenberg V; Mayer S; Shamul A; Barliya T; Cohen CJ
J Immunother Cancer; 2019 Sep; 7(1):243. PubMed ID: 31500665
[TBL] [Abstract][Full Text] [Related]
28. Adnectin-Based Design of Chimeric Antigen Receptor for T Cell Engineering.
Han X; Cinay GE; Zhao Y; Guo Y; Zhang X; Wang P
Mol Ther; 2017 Nov; 25(11):2466-2476. PubMed ID: 28784559
[TBL] [Abstract][Full Text] [Related]
29. A VHH-Based Anti-MUC1 Chimeric Antigen Receptor for Specific Retargeting of Human Primary T Cells to MUC1-Positive Cancer Cells.
Rajabzadeh A; Rahbarizadeh F; Ahmadvand D; Kabir Salmani M; Hamidieh AA
Cell J; 2021 Jan; 22(4):502-513. PubMed ID: 32347044
[TBL] [Abstract][Full Text] [Related]
30. CAR T cell therapy becomes CHIC: "cytokine help intensified CAR" T cells.
Thomas S; Abken H
Front Immunol; 2022; 13():1090959. PubMed ID: 36700225
[TBL] [Abstract][Full Text] [Related]
31. Influence of Retronectin-Mediated T-Cell Activation on Expansion and Phenotype of CD19-Specific Chimeric Antigen Receptor T Cells.
Stock S; Hoffmann JM; Schubert ML; Wang L; Wang S; Gong W; Neuber B; Gern U; Schmitt A; Müller-Tidow C; Dreger P; Schmitt M; Sellner L
Hum Gene Ther; 2018 Oct; 29(10):1167-1182. PubMed ID: 30024314
[TBL] [Abstract][Full Text] [Related]
32. Programmed cell death protein 1 activation preferentially inhibits CD28.CAR-T cells.
Zolov SN; Rietberg SP; Bonifant CL
Cytotherapy; 2018 Oct; 20(10):1259-1266. PubMed ID: 30309710
[TBL] [Abstract][Full Text] [Related]
33. Enhanced Cancer Immunotherapy by Chimeric Antigen Receptor-Modified T Cells Engineered to Secrete Checkpoint Inhibitors.
Li S; Siriwon N; Zhang X; Yang S; Jin T; He F; Kim YJ; Mac J; Lu Z; Wang S; Han X; Wang P
Clin Cancer Res; 2017 Nov; 23(22):6982-6992. PubMed ID: 28912137
[No Abstract] [Full Text] [Related]
34. Transgene-enforced co-stimulation of CD4+ T cells leads to enhanced and sustained anti-tumor effector functioning.
Chang L; Chang WC; McNamara G; Aguilar B; Ostberg JR; Jensen MC
Cytotherapy; 2007; 9(8):771-84. PubMed ID: 17917884
[TBL] [Abstract][Full Text] [Related]
35. [Specific cytotoxicity of a novel HER2-based chimeric antigen receptor modified T lymphocytes against HER2-positive tumor cells].
Tang HJ; Liu YQ; Bian XC; Feng HL; Gu B; Sun H; Zuo CX; Zhou FY; Liu J
Zhonghua Bing Li Xue Za Zhi; 2017 Oct; 46(10):714-720. PubMed ID: 29050075
[No Abstract] [Full Text] [Related]
36. Phosphoproteomic analysis of chimeric antigen receptor signaling reveals kinetic and quantitative differences that affect cell function.
Salter AI; Ivey RG; Kennedy JJ; Voillet V; Rajan A; Alderman EJ; Voytovich UJ; Lin C; Sommermeyer D; Liu L; Whiteaker JR; Gottardo R; Paulovich AG; Riddell SR
Sci Signal; 2018 Aug; 11(544):. PubMed ID: 30131370
[TBL] [Abstract][Full Text] [Related]
37. Manufacturing development and clinical production of NKG2D chimeric antigen receptor-expressing T cells for autologous adoptive cell therapy.
Murad JM; Baumeister SH; Werner L; Daley H; Trébéden-Negre H; Reder J; Sentman CL; Gilham D; Lehmann F; Snykers S; Sentman ML; Wade T; Schmucker A; Fanger MW; Dranoff G; Ritz J; Nikiforow S
Cytotherapy; 2018 Jul; 20(7):952-963. PubMed ID: 30180944
[TBL] [Abstract][Full Text] [Related]
38. T cells expressing VHH-directed oligoclonal chimeric HER2 antigen receptors: towards tumor-directed oligoclonal T cell therapy.
Jamnani FR; Rahbarizadeh F; Shokrgozar MA; Mahboudi F; Ahmadvand D; Sharifzadeh Z; Parhamifar L; Moghimi SM
Biochim Biophys Acta; 2014 Jan; 1840(1):378-86. PubMed ID: 24076235
[TBL] [Abstract][Full Text] [Related]
39. Combining T-cell immunotherapy and anti-androgen therapy for prostate cancer.
Sanchez C; Chan R; Bajgain P; Rambally S; Palapattu G; Mims M; Rooney CM; Leen AM; Brenner MK; Vera JF
Prostate Cancer Prostatic Dis; 2013 Jun; 16(2):123-31, S1. PubMed ID: 23295316
[TBL] [Abstract][Full Text] [Related]
40. Effective Targeting of Multiple B-Cell Maturation Antigen-Expressing Hematological Malignances by Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells.
Friedman KM; Garrett TE; Evans JW; Horton HM; Latimer HJ; Seidel SL; Horvath CJ; Morgan RA
Hum Gene Ther; 2018 May; 29(5):585-601. PubMed ID: 29641319
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
